Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally and the prognosis of unresectable HCC remains to be poor and provides significant challenges to patients. Chronic liver disease which most commonly influenced by hepatitis B and C viral infections but due to the development of anti-viral treatment, this is now a decreased risk factor for the development of HCC. Due to the common late detection of the disease, patients are most often diagnosed at an advanced stage and may not be able to therefore proceed with surgical treatment. Transarterial chemoembolization (TACE) is one of the most common non-surgical treatments for patients with intermediate to advanced HCC but has significant risk factors including post-therapy neoangiogenetic reaction or induce incomplete embolism which reduces the survival rate further. TACCE is most recommended for HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B who are not able to have surgical resection.
Studies have demonstrated that TACE when combined with other treatment modalities (including TACE plus tyrosine kinase inhibitors (TKIs) and TACE plus program-death receptor 1 (PD-1) inhibitor) is becoming more common for intermediate to advanced stage HCC patients and has shown improved efficacy. However TACE has been found to cause a hypoxic microenvironment which leads to the upregulation of hypoxia-inducible factor-1a (HIF-1a) which then upregulates the expression of VEGF and PDGF, and increase tumor angiogenesis and more studies are required to understand how TACE impacts HCC patients. The combination of TACE and TKIs to treat intermediate-stage HCC patients is currently being explored and improved as TACE monotherapy has not been found yet to provide a good clinical outcome to HCC patients.
The goal of this Research Topic is to generate a discussion of the impact of transarterial chemoembolization for hepatocellular carcinoma patients and how it impacts the survival rate and how it offers an alternative non-surgical treatment option. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally and the prognosis of unresectable HCC remains to be poor and provides significant challenges to patients. Chronic liver disease which most commonly influenced by hepatitis B and C viral infections but due to the development of anti-viral treatment, this is now a decreased risk factor for the development of HCC. Due to the common late detection of the disease, patients are most often diagnosed at an advanced stage and may not be able to therefore proceed with surgical treatment. Transarterial chemoembolization (TACE) is one of the most common non-surgical treatments for patients with intermediate to advanced HCC but has significant risk factors including post-therapy neoangiogenetic reaction or induce incomplete embolism which reduces the survival rate further. TACCE is most recommended for HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B who are not able to have surgical resection.
Studies have demonstrated that TACE when combined with other treatment modalities (including TACE plus tyrosine kinase inhibitors (TKIs) and TACE plus program-death receptor 1 (PD-1) inhibitor) is becoming more common for intermediate to advanced stage HCC patients and has shown improved efficacy. However TACE has been found to cause a hypoxic microenvironment which leads to the upregulation of hypoxia-inducible factor-1a (HIF-1a) which then upregulates the expression of VEGF and PDGF, and increase tumor angiogenesis and more studies are required to understand how TACE impacts HCC patients. The combination of TACE and TKIs to treat intermediate-stage HCC patients is currently being explored and improved as TACE monotherapy has not been found yet to provide a good clinical outcome to HCC patients.
The goal of this Research Topic is to generate a discussion of the impact of transarterial chemoembolization for hepatocellular carcinoma patients and how it impacts the survival rate and how it offers an alternative non-surgical treatment option. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
